Cartesian Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 6.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 204.22M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Details
| Name | Cartesian Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 75 |
| Founded | 2007 |
| Ipo Date | 2016-06-22 |
| Ceo | Carsten Brunn |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US8162123025 |
| Cusip | 816212302 |
| Cik | 0001453687 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Carsten Brunn Ph.D. | President, Chief Executive Officer and Chairman of the Board |
| Blaine T. Davis | Chief Financial Officer |
| Dr. Emily English Ph.D. | Chief Operating Officer |
| June Seymour | Chief Accounting Officer |
| Matthew Bartholomae J.D. | General Counsel and Secretary |
| Dr. Peter G. Traber M.D. | Head of Research & Development |
Contact
| Address | 7495 New Horizon Way, Frederick, Maryland 21703, United States |
| Phone | 301 348 8698 |
| Website | https://www.cartesiantherapeutics.com |